For instance, recent research efforts have suggested that SCLC comprises distinct molecular subtypes based on the expression of ASCL1, NEUROD1, POUF2F3, or YAP1 transcription factors translating into potentially distinct therapeutic vulnerabilities (Rudin et al. 2019; Ireland et al. 2020). This evidence concerns the gene NEUROD1 and small cell lung carcinoma.